28228055|t|Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients
28228055|a|To review the evidence regarding increased enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in the general trauma patient population. A search of MEDLINE databases (1946 to October 2016) was conducted using the search terms enoxaparin, thromboembolism prophylaxis, venous thromboembolism, trauma, anti-factor Xa, and weight -based dosing. Additional references were identified from a review of literature citations. Search results were limited to English-language studies conducted in humans. Trials that included only obese patients or nontrauma patients were excluded. A total of 7 trials (958 patients) explored the use of increased dosing of enoxaparin for VTE prophylaxis in trauma patients. Patients were divided by enoxaparin dosing strategies: standard dosing of 30 mg twice daily (BID; n = 509), higher initial dosing regimen (n = 216), or dosing based on anti-FXa level adjustments (n = 233). The majority of the 42 total VTE events (64.3%) occurred in the standard dosing regimen. Within each group, VTE was reported in 5.3% of patients in the standard dosing group, 3.2% in the higher initial dosing group, and 4% in the anti-FXa adjustment group. Initial subtherapeutic anti-FXa levels occurred in 33% to 92% of standard dose patients and 9% to 39% of higher initial dose patients. The average weight -based dose required to achieve a therapeutic level ranged between 0.43 and 0.54 mg/kg/ dose BID. The overall rate of bleeding was low, with 3 incidents (0.37%) reported. Standard - dose enoxaparin prophylaxis may not be optimal for the general trauma patient population. Weight -based enoxaparin dosing (0.5 mg/kg/ dose BID) is an option in trauma patients considered to be at a lower risk of bleeding complications.
28228055	10	20	Enoxaparin	T103	UMLS:C0206460
28228055	32	66	Venous Thromboembolism Prophylaxis	T058	UMLS:C0199242
28228055	78	84	Trauma	T037	UMLS:C3714660
28228055	137	147	enoxaparin	T103	UMLS:C0206460
28228055	159	199	venous thromboembolism (VTE) prophylaxis	T058	UMLS:C0199242
28228055	215	221	trauma	T037	UMLS:C3714660
28228055	230	240	population	T098	UMLS:C1257890
28228055	254	271	MEDLINE databases	T170	UMLS:C0025141
28228055	332	342	enoxaparin	T103	UMLS:C0206460
28228055	344	371	thromboembolism prophylaxis	T058	UMLS:C0199242
28228055	373	395	venous thromboembolism	T038	UMLS:C1861172
28228055	397	403	trauma	T037	UMLS:C3714660
28228055	405	419	anti-factor Xa	T103	UMLS:C0443793
28228055	492	512	review of literature	T170	UMLS:C0282441
28228055	513	522	citations	T170	UMLS:C0552371
28228055	572	579	studies	T062	UMLS:C2603343
28228055	593	599	humans	T204	UMLS:C0086418
28228055	601	607	Trials	T062	UMLS:C0008976
28228055	627	632	obese	T038	UMLS:C0028754
28228055	692	698	trials	T062	UMLS:C0008976
28228055	754	764	enoxaparin	T103	UMLS:C0206460
28228055	769	784	VTE prophylaxis	T058	UMLS:C0199242
28228055	788	794	trauma	T037	UMLS:C3714660
28228055	830	840	enoxaparin	T103	UMLS:C0206460
28228055	935	942	regimen	T058	UMLS:C0040808
28228055	973	987	anti-FXa level	T033	UMLS:C1318056
28228055	988	999	adjustments	T058	UMLS:C2945673
28228055	1040	1043	VTE	T038	UMLS:C1861172
28228055	1091	1098	regimen	T058	UMLS:C0040808
28228055	1119	1122	VTE	T038	UMLS:C1861172
28228055	1241	1249	anti-FXa	T103	UMLS:C0443793
28228055	1250	1260	adjustment	T058	UMLS:C2945673
28228055	1291	1306	anti-FXa levels	T033	UMLS:C1318056
28228055	1456	1473	therapeutic level	T033	UMLS:C0580398
28228055	1540	1548	bleeding	T038	UMLS:C0019080
28228055	1609	1619	enoxaparin	T103	UMLS:C0206460
28228055	1620	1631	prophylaxis	T058	UMLS:C0199242
28228055	1667	1673	trauma	T037	UMLS:C3714660
28228055	1682	1692	population	T098	UMLS:C1257890
28228055	1708	1718	enoxaparin	T103	UMLS:C0206460
28228055	1764	1770	trauma	T037	UMLS:C3714660
28228055	1816	1824	bleeding	T038	UMLS:C0019080
28228055	1825	1838	complications	T038	UMLS:C0009566